The recent slump in Wall Street’s previously favoured growth stocks, especially those tied to heavy AI spending, has pushed many investors to rethink where they look for future winners. This is where fast growing Australian businesses with high insider ownership can be interesting. When founders and executives keep meaningful stakes, their incentives are closely aligned with yours. This article highlights three stocks from that group that may be worth a closer look.
The three stocks highlighted here offer a compelling starting point if you want exposure to fast growing businesses where insiders and external analysts share an optimistic outlook. However, if you want the pick of this theme, these 26 high growth high conviction stocks are the best of the best.
Regis Healthcare (ASX:REG)
Overview: Regis Healthcare runs residential aged care homes and home care services across Australia, focused on ageing in place and higher acuity support.
Operations: Regis Healthcare generates about A$1.35b in revenue from residential aged care, home care and retirement living services entirely within Australia.
Market Cap: A$1.45b
Regis Healthcare taps directly into the screener’s theme through its expanding network of aged care homes and home care services. Management and analysts both see room for further growth as demand for higher acuity, premium care deepens.
"While higher room pricing and an average incoming RAD close to A$700,000 are already feeding into stronger RAD inflows, the uplift depends on continued demand for premium accommodation and timely IHACPA approvals, which could moderate the pace of revenue and RAD retention driven earnings growth."
The key variable is how one evolving policy and cost backdrop ultimately feeds through to pricing power and long term margins.
That hinges on more than policy settings alone, so read the full narrative for Regis Healthcare to see how pricing, capital needs and resident mix could be decoupling beneath the surface.
Liontown (ASX:LTR)
Overview: Liontown focuses on developing the Kathleen Valley lithium project in Western Australia, with additional exploration exposure to gold and nickel.
Operations: Liontown generated A$639 million from exploration and development of mineral projects, with all revenue sourced within Australia.
Market Cap: A$2.0b
Liontown is connected to the fast growing, insider-backed theme through Kathleen Valley, where management is working to improve lithium recoveries and cost efficiency.
"The company has initiated trials with higher contamination ore, achieving higher lithium recovery rates while maintaining strong recovery even with lower-grade material, which could affect net margins by optimizing processing costs over time."
What may significantly influence outcomes is how one evolving cost pressure interacts with that recovery work to shape long term profitability.
That margin tug of war is only one piece of the story, so read the full narrative for Liontown to see how Liontown’s risk reward profile could be shifting.
Telix Pharmaceuticals (ASX:TLX)
Overview: Telix Pharmaceuticals develops and commercialises radiopharmaceutical diagnostics and therapies that help doctors find and treat cancers using targeted precision medicine.
Operations: Telix generates about US$705 million from Precision Medicine and US$277 million from Manufacturing Solutions, with inter-segment eliminations of US$96 million.
Market Cap: A$4.46b
Telix Pharmaceuticals fits the fast growing, insider-backed theme through its late stage theranostics pipeline, where TLX591 and companion imaging agents could potentially reshape how major cancers are found and treated if clinical and regulatory milestones line up.
"Their primary revenue generating imaging agents: 'Illuccix' and 'Gozellix', are utilised in 23+ countries worldwide, including key markets such as the U.S, Europe, China and Japan, with revenue figures of $803.8m (USD) in the 2025 Financial Year (within their already upgraded guidance range) provided for FY25, a cash balance of $141.9m (USD), and the potential growth of Gozellix as its launch into the U.S expands."
What really tests that fast growth story is how one unresolved pressure shapes the balance between funding hungry trials and future pricing power.
If that funding trade off matters to you, read the full narrative for Telix Pharmaceuticals to see whether Telix Pharmaceuticals’ current momentum is masking bigger long term swings.
Seeking Fresh Alternatives For Your Watchlist
New ideas move first. By the time a breakout story hits the front page, early momentum is often gone. Scan these fresh picks before the crowd and act now.
- Target reliable cash generators and scan a curated list of solid balance sheet and fundamentals (12 results) before these steadier operators get fully priced by everyone else.
- Hunt for pricing power and income resilience with a focused pass through 4 dividend fortresses before yields compress and the easy payout opportunities get caught by yield chasers.
- Ride structural shifts in energy demand by reviewing 16 nuclear energy infrastructure stocks while these potential infrastructure beneficiaries are still under the radar for now.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com